Navigation Links
Trovagene Announces Issuance of Broad MicroRNA Patent
Date:7/24/2013

SAN DIEGO, July 24, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced the issuance of US patent 8,486,626, "Methods of detecting cell-free miRNA in urine and blood." The patent pertains to the detection and quantitation of microRNA (miRNA) using a wide variety of technologies and platforms. MicroRNAs are known to play critical roles in cell development as well as a number of diseases, including cancer.

(Logo:  http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

"MicroRNA signatures are highly sensitive biomarkers with the potential to be used in a wide range of molecular diagnostic tests," states Mark Erlander, Ph.D., chief scientific officer of Trovagene.  "They have been shown to have varying expression levels across numerous pathological conditions including cancer, autoimmune and inflammatory diseases and cardiovascular diseases."

Despite their relatively recent discovery and characterization, several miRNA-based therapeutics have entered clinical trials, confirming their importance as critical regulators of human disease. "MicroRNAs hold the promise of yielding a new class of therapeutics in addition to current diagnostic uses," adds Erlander.

The new miRNA patent extends Trovagene's established intellectual property portfolio in the field of cell-free molecular diagnostics, which covers DNA and RNA fragments found in urine.  Trovagene already has proprietary methods around the isolation, detection and analysis of these cell-free nucleic acids from urine, a non-invasive and easy to obtain sample type.

"Cell-free nucleic acids, including microRNAs, are an integral part of our company's focus on cancer diagnostics. Our newly established patent position in microRNA detection in blood and urine will complement our proprietary capabilities to detect and quantify DNA mutations and genetic variations," said Antonius Schuh, Ph.D., chief executive officer of Trovagene. "We believe this technology promises to have a profound impact on the field of cancer diagnostics."

About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.

Contact:

Trovagene, Inc.       

Stephen Zaniboni
Chief Financial Officer
Trovagene, Inc.
858-952-7594
szaniboni@trovagene.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Trovagene, Inc., Announces Fourth Quarter and Year End 2012 Earnings
2. Trovagene Launches Urine-Based HPV Test
3. Trovagene Appoints Mark Erlander, Ph.D. as Chief Scientific Officer
4. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
5. Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
6. Trovagene and Barretos Cancer Hospital, Brazil, to Evaluate Urine-Based HPV Assay as Potential Pap Smear Replacement
7. Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
8. Dr. Paul Billings joins Trovagenes Scientific Advisory Board
9. Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update
10. Trovagene and Strand Life Sciences Agree to Validate and Commercialize Urine-Based HPV Test in India and South Asia
11. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... -- The Global Effective Microorganisms (EM) Market by ... covered and analysed the potential of Global Effective Microorganisms (EM) ... and growth factors. The report identifies and analyses the emerging ... global market. ... Tables and Figures, 6 Major Company Profiles, spread across 124 ...
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
Breaking Medicine Technology:
(Date:4/21/2017)... TX (PRWEB) , ... April 21, 2017 , ... ... Care products, announced an exciting new partnership with the highly regarded and well ... Airway Management’s highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will ...
(Date:4/21/2017)... Malvern, Worcestershire, UK (PRWEB) , ... April 21, ... ... Queen’s Award for Enterprise in the category of International Trade, the UK’s most ... performance in international trade, which represents 95% of total revenues and has grown ...
(Date:4/21/2017)... Ramon, CA (PRWEB) , ... April 21, 2017 , ... ... might not understand the estate planning process, or where to even begin. “Now more ... unresolved if you are to properly protect yourself and your family,” said attorney Lisa ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Westside Dental ... personalized dental care since 1985. After thirty-two years, Dr. Latner has become one of ... help my numerous clients over the years with all their dental needs,” said Dr. ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Each year, ... is a day to clean, plant trees and look forward to a better future. ... just about doing something outdoors. Indoor air quality can be two to five times ...
Breaking Medicine News(10 mins):